From Nasdaq: 2025-05-27 07:55:00

Biogen Inc. and City Therapeutics announce a strategic collaboration to develop novel RNAi therapies focusing on CNS diseases. City Therapeutics will use RNAi engineering technologies combined with Biogen’s drug delivery tech. Biogen will lead IND studies, clinical development, regulatory submissions, and commercialization. City Therapeutics will receive $46 million, including $16 million upfront and a $30 million investment for a convertible note. Potential milestone payments could reach up to $1 billion, plus royalties based on net sales. Biogen may choose an additional target for collaboration with an extra payment.



Read more at Nasdaq: Biogen Partners City Therapeutics To Develop Select Novel RNAi Therapies